Mirum Pharmaceuticals, Inc.
MIRM
$102.19
-$9.21-8.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 43.28% | 49.81% | 47.17% | 64.09% | 61.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.28% | 49.81% | 47.17% | 64.09% | 61.20% |
| Cost of Revenue | 25.14% | 24.07% | 22.74% | 15.79% | 29.10% |
| Gross Profit | 48.00% | 57.46% | 54.48% | 81.04% | 72.34% |
| SG&A Expenses | 66.93% | 30.44% | 22.48% | 28.61% | 26.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.17% | 24.15% | 26.53% | 30.03% | 27.25% |
| Operating Income | -520.28% | 81.15% | 120.52% | 79.41% | 61.53% |
| Income Before Tax | -5,686.05% | 79.63% | 119.03% | 77.26% | 44.64% |
| Income Tax Expenses | -53.84% | 233.16% | -175.50% | -36.69% | 64.90% |
| Earnings from Continuing Operations | -5,283.63% | 75.91% | 120.41% | 76.21% | 41.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5,283.63% | 75.91% | 120.41% | 76.21% | 41.94% |
| EBIT | -520.28% | 81.15% | 120.52% | 79.41% | 61.53% |
| EBITDA | -1,262.60% | 108.30% | 230.71% | 105.81% | 80.14% |
| EPS Basic | -4,372.49% | 77.21% | 119.27% | 77.40% | 44.27% |
| Normalized Basic EPS | -518.17% | 80.72% | 117.94% | 78.40% | 66.32% |
| EPS Diluted | -4,372.49% | 75.41% | 116.67% | 77.40% | 44.27% |
| Normalized Diluted EPS | -518.17% | 80.72% | 115.96% | 78.40% | 66.32% |
| Average Basic Shares Outstanding | 20.38% | 5.63% | 5.98% | 5.28% | 4.18% |
| Average Diluted Shares Outstanding | 20.38% | 5.63% | 19.28% | 5.28% | 4.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |